Economic analysis of Noqturina® (oral lyophilisate) use in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 2, Issue 2
Abstract
Introduction: Nocturia relates to the need to urinate at night when micturition was preceded by sleep and immediately followed by a period of sleep. The aim of this analysis is to examine the cost-effectiveness of desmopressin at a dose of 25 μg oral lyophilisate for women and 50 μg oral lyophilisate for men (DDAVP) in comparison to the best supportive care (BSC) used in Polish clinical practice in the treatment of nocturia (≥2 nocturnal micturition) caused by idiopathic nocturnal polyuria. Methods: The economic analysis uses a model combining the aspects of the partitioned-survival model and state-transition model (STM). The projection was carried out over a 30-year time horizon, which corresponds to 120 quarterly modelling cycles. The costs were calculated from a common perspective, including expenses incurred by the public payer (Narodowy Fundusz Zdrowia, National Health Found) and expenses incurred by the patient. Health effects of medical technologies have been estimated on the basis of unit data from CS40 and CS41 studies. The literature, statistical databases and information provided by clinical experts were used to develop the remaining input data, including utility. Results: The ICER for DDAVP + BSC compared to BSC was 56.1 kPLN (13.0 kEUR) and is below the cost-effectiveness threshold in force in Poland (135.5 kPLN; 31.2 kEUR). The multi-directional sensitivity analysis shows a profitability rate of 98.6%. Conclusions: The economic model shows that the addition of orodispersible DDAVP to standard treatment allows reducing the expected number of nocturnal micturition, improving the quality of life and reducing the number of injuries and fractures in the group of patients with nocturia caused by idiopathic nocturnal polyuria. Considering the total direct medical costs of treatment, desmopressin administered at a dose of 25 μg for women and 50 μg for men is a cost-effective therapy when added to the BSC.
Authors and Affiliations
Maciej Dzik, Grzegorz Binowski, Piotr Chłosta, Jakub Dobruch, Paweł Miotła, Tomasz Rechberger, Adam Bierut
Keywords
Related Articles
- EP ID EP532128
- DOI 10.7365/JHPOR.2018.2.1
- Views 64
- Downloads 0
Cancer immunotherapy in second-line treatment of non-small cell lung cancer – is there a need to change the approach to the assessment of clinical benefits?
Background: The mechanism of action distinctive for immunotherapy leads to the specific pattern of tumour response, different form the one observed with cytotoxic therapy. To enable a complete assessment of immunotherape...
Optimization of approaches to the treatment of metastatic colorectal cancer wild-type gene KRAS
The results of the literature review of drug use for the treatment of metastatic colorectal cancer (mCRC) are presented. Analysis of the data showed that cetuximab (Erbitux) and panitumumab (Vectibix) are effective drugs...
Adoption of Real World Evidence in decision-making processes on public funding of drugs in Poland
Background: The aim of the study was to assess the use and impact of RWE in decision-making processes on public funding of drugs in Poland. Methods: The analysis was based on data from the Agency for Health Technology A...
The study of the need for interprofessional collaboration in the health care system in Poland - experience of Lesław A. Paga Foundation.
Background: Interprofessional collaboration (IC) in healthcare is a process by which professionals from different disciplines collaborate to provide an integrated and cohesive approach to patient care. The Lesław A. Paga...
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...